Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio ...

(HSCT) following U.S. FDA approval of Tregzi, a first-of-its-kind, personalized cell therapy. Previously known as Orca-T, Tregzi is indicated for use in matched-donor HSCT with myeloablative ...

Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Candela, Cerenome, Eli Lilly, Innovent, Kyowa, Orion, Pacira, Plus, Shilpa, Zimmer.

MED-EL Elektromedizinische Geräte GmbH has acquired two gene therapy programs from Rescue Hearing Inc. for genetic hearing and balance disorders.

Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics ...

Researchers at East China Normal University and collaborators reported the discovery and optimization of a series of SUCNR1 antagonists for cancer immunotherapy.

The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are ...

Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of ...

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill patients have received an implant to treat ...

New hires and promotions in the biopharma and med-tech industries in Asia-Pacific, including: Respiree.

Pacific, including data readouts and publications: Hutchmed, Otsuka.